Major Depressive Disorder adjunctive treatment
搜索文档
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
Globenewswire· 2026-11-16 20:00
HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points -7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001) Durable effect maintained through Week 12 (key secondary endpoint) with a -7.0 point placebo-adjusted change from baseline on the MADRS (p< 0.0001) Robust and statistically sign ...